Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Diffuse Lewy body disease]

M Yoshimura1

  • 1Department of Pathology, Tokyo Metropolitan Medical Examiner's Office.

Rinsho Shinkeigaku = Clinical Neurology
|May 13, 1998
PubMed
Summary
This summary is machine-generated.

Lewy body disease (LBD) involves progressive neurological decline with parkinsonism and Lewy bodies (LBs). Diffuse Lewy body disease (DLBD) features abundant LBs in the cortex, differing from Parkinson's disease and Alzheimer's disease neurochemically.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Combination therapy of doxifluridine, pirarubicin and cisplatin for human gastric cancers implanted in nude mice].

Gan to kagaku ryoho. Cancer & chemotherapy·1995
Same author

Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection.

Proceedings of the National Academy of Sciences of the United States of America·1995
Same author

Effect of the transmembrane gradient of magnesium and sodium on the regulation of cytosolic free magnesium concentration in human platelets.

Clinical science (London, England : 1979)·1995
Same author

[Short somatosensory evoked potentials in patients with Fukuyama type congenital muscular dystrophy--a comparison with CT and MRI findings].

No to hattatsu = Brain and development·1995
Same author

Heat-shock cognate 70 messenger RNA expression in postmortem human hippocampus: regional differences and age-related changes.

Neuroscience letters·1995
Same author

[Renal arterial disease-induced tubulo-interstitial lesions].

Nihon rinsho. Japanese journal of clinical medicine·1995
Same journal

[Let's present at a regional meeting].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Editor's Note].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Notice for Members].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[The Proceedings of the 250th Kyushu Regional Meeting of the Japanese Society of Neurology].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[The Proceedings of the 116th Tohoku Regional Meeting of the Japanese Society of Neurology].

Rinsho shinkeigaku = Clinical neurology·2026
Same journal

[Metagenomic analysis for central nervous system infections: clinical utility and future directions].

Rinsho shinkeigaku = Clinical neurology·2026
See all related articles

Area of Science:

  • Neuropathology
  • Neurodegenerative Diseases

Context:

  • Lewy body disease (LBD) is a spectrum of disorders characterized by Lewy bodies (LBs).
  • LBD classification includes brain-stem, transitional, and diffuse types.
  • Diffuse Lewy body disease (DLBD) is a distinct neuropathological entity.

Purpose:

  • To describe the neuropathological characteristics of Diffuse Lewy Body Disease (DLBD).
  • To outline the clinical manifestations and neurochemical profile of DLBD.
  • To differentiate DLBD from Parkinson's disease (PD) and Alzheimer's disease (AD).

Summary:

  • DLBD is defined by abundant Lewy bodies (LBs) in the cerebral cortex, basal ganglia, and brain-stem.
  • Clinical features include progressive dementia, psychosis, parkinsonism, and autonomic dysfunction.

Related Experiment Videos

  • Neurochemically, DLBD shows impairment in cholinergic and dopaminergic systems, distinguishing it from PD and AD.

    • Impact:

    • Understanding DLBD's unique neuropathology and clinical presentation is crucial for accurate diagnosis.
    • Identifying specific neurochemical deficits aids in differentiating DLBD from other neurodegenerative disorders.
    • This knowledge can inform future therapeutic strategies targeting specific neurotransmitter systems.